The Microcirculation in Acute Myocardial Infarction (Micro-AMI) (Micro-AMI)

October 27, 2014 updated by: Elisa McAlindon, University of Bristol
This study investigates the association between the microvascular resistance at the time of primary percutaneous intervention, with microvascular obstruction on CMR and blood markers of myocardial damage.

Study Overview

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bristol, United Kingdom, BS2 8HW
        • Bristol Heart Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

STEMI attending Bristol Heart Institute via the primary PCI service

Description

Inclusion Criteria:

  • >18 years old
  • Cardiac symptoms of > 20 mins chest pain or equivalent.
  • ECG criteria consistent with STEMI (STEMI)
  • Proceeding with percutaneous angioplasty
  • Assent/ consent to the study

Exclusion Criteria:

  • Known allergy to adenosine or gadolinium
  • Chronic atrial fibrillation
  • Renal impairment with eGFR <30
  • Contraindication to angiography
  • Contraindication to CMR (implanted pacemaker/ defibrillator, ferromagnetic metal implant/ injury, claustrophobia, obesity/ too large for CMR scanner)
  • Cardiogenic shock
  • Patients with special communication needs or altered consciousness.
  • Patients who do not give assent/consent to the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
STEMI patients
Consecutive patients presenting through the PPCI service

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microvascular obstruction
Time Frame: DAy 2-4
Microvascular obstruction as a percentage of the left ventricle at 2-4 days.
DAy 2-4

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (Actual)

January 1, 2014

Study Registration Dates

First Submitted

March 9, 2012

First Submitted That Met QC Criteria

March 12, 2012

First Posted (Estimate)

March 13, 2012

Study Record Updates

Last Update Posted (Estimate)

October 28, 2014

Last Update Submitted That Met QC Criteria

October 27, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on STEMI

Clinical Trials on Index of microvascular resistance

Subscribe